entertainment -WSS

entertainment

author：entertainment 2025-09-27 15:19:26 - browse：4

Stock exchange — Drew Angerer/Getty Images

Structure Therapeutics reported Monday that its oral GLP-1 drug led to weight loss in two small studies, leading shares to surge in pre-market trading.

In a 12-week Phase 2a study, the daily pill in a capsule formulation led to 6.2% placebo-adjusted weight loss. In a separate 12-week pharmacokinetics study, the company tested a new tablet formulation of the drug, called GSBR-1290, and it led to placebo-adjusted weight loss of up to 6.9%.

Though it’s difficult to compare across different studies, the results appear to approach the levels of weight loss seen at 12 weeks in a separate Phase 2 study of Eli Lilly’s GLP-1 pill called orforglipron. That entire study lasted 36 weeks, but at 12 weeks, participants had about 6%-7% placebo-adjusted weight loss.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： FDA approves potent Eli Lilly obesity drug, Zepbound

WSS

Virtual Event: March of the Biosimilars

U.K. researchers warn about biases in medical devices, algorithms

Leading voice in opioid treatment defends methadone clinic system

Creating egg and sperm cells from stem cells raises ethical issues

Free speech concerns arise in wake of journal editor Eisen's firing

FDA approves potent Eli Lilly obesity drug, Zepbound

explore

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

Heart attack and stroke risk calculators need revising

Study: New antibiotic targets gonorrhea as well as last existing drug

Anesthesiologist group: stop taking Ozempic before surgery

Diversify hospital leadership teams to protect BIPOC patient health

Peter Hotez and the public health issue of online harassment

Positive childhood experiences can help future health

Heart attack and stroke risk calculators need revising

More doctors should go into startup world

Anesthesiologist group: stop taking Ozempic before surgery

U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

entertainment

HPV cancer vaccine study demonstrates efficacy

Sanofi CEO defends move to abandon profit guidance, boost research

AstraZeneca to buy developer of next

Future doctors should be trained to promote social change

Health AI adoption puts security, privacy startups on investors' radar

Future doctors should be trained to promote social change

leisure time

Wikipedia

focus

explore